(Q46563279)

23 December 2017

editorial

0 references

title

Genetic basis for predicting response to naltrexone in the treatment of alcohol dependence (English)

1 reference

23 December 2017

0 references

Raymond F Anton

1

1 reference

23 December 2017

publication date

1 June 2008

1 reference

23 December 2017

published in

Pharmacogenomics

1 reference

23 December 2017

volume

9

1 reference

23 December 2017

issue

6

1 reference

23 December 2017

page(s)

655-658

1 reference

23 December 2017

The 12-month prevalence and trends in DSM-IV alcohol abuse and dependence: United States, 1991-1992 and 2001-2002.

cites work

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.6.655

Topiramate for treating alcohol dependence: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.6.655

Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.6.655

Naltrexone for the treatment of alcoholism: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.6.655

Naltrexone decreases craving and alcohol self-administration in alcohol-dependent subjects and activates the hypothalamo-pituitary-adrenocortical axis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.6.655

Predicting treatment response to naltrexone: the influence of craving and family history

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.6.655

Clinical predictors of response to naltrexone in alcoholic patients: who benefits most from treatment with naltrexone?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.6.655

Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.6.655

Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.6.655

Effect of the A118G polymorphism on binding affinity, potency and agonist-mediated endocytosis, desensitization, and resensitization of the human mu-opioid receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.6.655

Allelic expression imbalance of human mu opioid receptor (OPRM1) caused by variant A118G.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.6.655

A polymorphism of the mu-opioid receptor gene (OPRM1) and sensitivity to the effects of alcohol in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.6.655

A functional polymorphism of the mu-opioid receptor gene (OPRM1) influences cue-induced craving for alcohol in male heavy drinkers.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.6.655

The human mu-opioid receptor gene polymorphism 118A > G decreases cortical activation in response to specific nociceptive stimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.6.655

The mu-opioid receptor gene polymorphism (A118G) alters HPA axis activation induced by opioid receptor blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.6.655

A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.6.655

Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.6.655

An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.6.655

Effect of naltrexone and ondansetron on alcohol cue-induced activation of the ventral striatum in alcohol-dependent people

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.6.655

Naltrexone effects on alcohol consumption in a clinical laboratory paradigm: temporal effects of drinking

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.6.655

Efficacy of Naltrexone and Acamprosate for Alcoholism Treatment: A Meta-Analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.6.655

21 January 2018

Identifiers

DOI

10.2217/14622416.9.6.655

1 reference

23 December 2017

1 reference

23 December 2017